Novo Nordisk launches $499 Wegovy cash option and home delivery

Key Points

  • Novo Nordisk (NVO) introduces a new cash-pay option for Wegovy at $499 per month, following Eli Lilly's (LLY) similar move for Zepbound.
  • The new pricing strategy aims to increase access to weight-loss drugs as demand grows and branded shortages end, potentially facing competition from unbranded knockoffs.
  • The cash price is significantly lower than the list price, offering a 50% or more discount, making it more accessible to uninsured patients or those without coverage for these drugs.
  • Novo Nordisk's stock rose over 4% after the announcement, reflecting positive market response to the new pricing strategy.

Summary

Novo Nordisk has launched a new cash-pay option for its weight-loss drug Wegovy, setting the price at $499 per month with home delivery. This move mirrors a similar strategy by competitor Eli Lilly for its drug Zepbound, aiming to meet the increasing demand for these GLP-1 medications. The introduction of these cash programs comes at a time when the FDA has declared that the drugs are no longer in shortage, potentially opening the market to unbranded versions from compounding pharmacies. The new pricing offers a significant discount from the list price, making it more affordable for patients without insurance coverage or those whose insurance does not cover weight-loss drugs. This initiative is part of a new business segment called NovoCare Pharmacy. Following the announcement, Novo Nordisk's stock saw a notable increase, indicating a positive market reaction to the strategy. However, the program is limited to certain patients, specifically those uninsured or with commercial insurance lacking coverage for these medications.

yahoo
March 5, 2025
Stocks
Read article

Related news